Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (131-140 of 251) with videos related to

Pageof 26
Sort By:
Clinical Epigenetics|October 14, 2019
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutationSylvain Garciaz, Lia N'guyen Dasi, Pascal Finetti, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
British Journal of Haematology|October 1, 2010
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Cancers|April 23, 2022
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia PatientsSylvain Garciaz, Marie-Anne Hospital, Anne-Sophie Alary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2015
Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated DonorDidier Blaise, Sabine Fürst, Roberto Crocchiolo, et al.
Annals of Hematology|May 10, 2011
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma levelLaurence Legros, Bohrane Slama, Jean-Michel Karsenti, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Pageof 26

Showing results (131-140 of 251) with videos related to

Sort By:
Pageof 26
Clinical Epigenetics|October 14, 2019
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutationSylvain Garciaz, Lia N'guyen Dasi, Pascal Finetti, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
British Journal of Haematology|October 1, 2010
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Emmanuel Raffoux, Xavier Thomas, et al.
Cancers|April 23, 2022
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia PatientsSylvain Garciaz, Marie-Anne Hospital, Anne-Sophie Alary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2015
Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated DonorDidier Blaise, Sabine Fürst, Roberto Crocchiolo, et al.
Annals of Hematology|May 10, 2011
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma levelLaurence Legros, Bohrane Slama, Jean-Michel Karsenti, et al.
Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.
Pageof 26